secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001193125-26-056135
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%
--------------------------------------------------------------------------------

- Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.
- Sold 14,440 Series B Preferred shares in $200M PIPE; post-PIPE: PIPE investors ~54.3%, Faeth ~40.8%, Sensei ~4.9%.
- Anand Parikh (ex-Faeth CEO) appointed as COO and director; granted 1,239,305 option inducement award vesting over 4 years.
- Certificate of Designation filed; conversion of Series B requires stockholder approval and beneficial ownership limits of 4.99%-19.99%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/0001193125-26-056135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-056135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer